Ratification open for the 2026 - 2029 Board of Directors Slate
This year, ISPOR is implementing updated procedures for Board selection, transitioning to an uncontested election process. You can learn more about the new approach here. The ISPOR Nominations Committee has proposed a slate of candidates, with one nominee for each open Director position.
Ratification of the slate of Directors is imperative and requires participation of at least 3% of the membership. Thank you in advance for voting by April 3, 2026.
Please review the Directors selected by the ISPOR Nominations Committee and ratify the slate by clicking here:
Director 1
Sandra Nestler-Parr, MSc, MPhil, PhD
Senior Vice President, Value & Patient Access
BioCryst Pharmaceuticals
Durham, NC, USA
Director 2
William Padula, PhD
Associate Professor, University of Southern CA
Los Angeles, CA, US
Director 3
Jing Wu, PhD
Chair, Pharmacoeconomics Professional Committee
Chinese Pharmaceutical Association
Beijing, China
As per ISPOR’s bylaws, members were given the opportunity to add additional nominees through a petition process where qualified members not named by the Nominations Committee can obtain member signatures to appear on the ballot. No additional candidates were added through the petition process.
The Board will choose the President-elect and Treasurer based on recommendations from the Nominations Committee.
Your vote is important in shaping the future of ISPOR.
Brian O’Rourke
2026 Chair, ISPOR Nominations Committee
***As a member you must log-in to your profile to access the ballot.
Forgot your password? Click here
Please contact membership@ispor.org for login issues.
Please contact governance@ispor.org with questions related to the elections.